Vera Therapeutics (VERA) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vera Therapeutics (VERA) has outperformed Viridian Therapeutics (VRDN) over the past year, losing 2.1% versus a loss of 14.4%. Over five years, VERA leads with a +99.1% price change compared with +9.3% for VRDN. Vera Therapeutics is the larger company by market cap ($2.15 billion vs $2.11 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VERA | VRDN |
|---|---|---|
| Share price | $29.88 | $18.66 |
| Market cap | $2.15B | $2.11B |
| 1-day change | +0.50% | +1.74% |
| YTD return | -41.00% | -40.04% |
| 1-year return | -2.13% | -14.44% |
| 5-year return | +99.07% | +9.31% |
| EPS (TTM) | $-5.87 | $-3.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $70.85M |
| Revenue growth (YoY) | — | +23359.93% |
| Net income (latest FY) | $-299.62M | $-342.60M |
| Operating margin | — | -512.91% |
| Net margin | — | -483.57% |
| 52-week high | $56.05 | $34.29 |
| 52-week low | $23.05 | $13.18 |
| Distance from 52-week high | -46.69% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +159.37% | +96.95% |
| Average volume | 2.21M | 1.71M |
| Shares outstanding | 72.06M | 113.29M |
| Employees | 361 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERA has outperformed VRDN by 12.3 percentage points over the past year.
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
VERA vs VRDN FAQ
Which is bigger, Vera Therapeutics or Viridian Therapeutics?
Vera Therapeutics (VERA) is larger, with a market capitalization of $2.15B compared with $2.11B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, VERA or VRDN?
VERA returned -2.13% over the past 12 months, compared with -14.44% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Vera Therapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.